Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 6/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 3/20 | 1.00 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.57 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.57 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.51 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 0.51 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 0.51 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5453930 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1NT5E | |
| Hydrochloric Acid SCHEMBL1770829 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1NT5E | |
| Hydrochloric Acid SCHEMBL2474313 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1NT5E | |
| Hydrochloric Acid SCHEMBL6559174 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1NT5E | |
| Hydrochloric Acid SCHEMBL6559893 | 0.98 | ROCK2 (0.97) | ROCK2ROCK1KDM4EL3MBTL1NT5E | |
| Hydrochloric Acid SCHEMBL6559887 | 0.98 | ROCK2 (0.97) | ROCK2ROCK1KDM4EL3MBTL1NT5E | |
| SCHEMBL1553353 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1NT5E | |
| SCHEMBL1554113 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1NT5E | |
| SCHEMBL1553349 | 0.98 | ROCK2 (1.00) | ROCK2ROCK1KDM4EL3MBTL1NT5E | |
| SCHEMBL5463779 | 0.87 | ROCK2 (0.78) | ROCK2ROCK1KDM4EL3MBTL1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016081554-A1 | IMMUNOGENIC COMPOSITIONS PREPARED FROM TUMOR CELLS DERIVED FROM PERIPHERAL BLOOD AND ORIGINATING FROM A SOLID TUMOR AND THEIR USE | NEOSTEM ONCOLOGY, LLC (US) | 2016-05-26 | — | — | WO | claimed |
| US-20260028584-A1 | METHOD FOR EVALUATING AGGREGATION-SUPPRESSING ACTIVITY OR AGGREGATION-PROMOTING ACTIVITY ON AGGREGATING PROTEIN USING ORGANOID, AND METHOD FOR PRODUCING ORGANOID | KANEKA CORPORATION (JP) | 2026-01-29 | — | — | US | disclosed |
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | disclosed |
| US-20250250539-A1 | METHOD FOR EVALUATING ACTIVITY OF INHIBITING OR PROMOTING AGGREGATION OF AGGREGATING PROTEINS | KANEKA CORPORATION (JP) | 2025-08-07 | — | — | US | disclosed |
| EP-4597103-A1 | METHOD FOR ASSESSING COAGULATION INHIBITION ACTIVITY OR COAGULATION PROMOTION ACTIVITY AGAINST COAGULATIVE PROTEIN | Kaneka Corporation (JP) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025058089-A1 | AGENT FOR SUPPRESSING AMYLOID β AGGREGATION/DEPOSITION AND AGENT FOR SUPPRESSING/IMPROVING COGNITIVE DECLINE OF SUBJECT | 株式会社カネカ | 2025-03-20 | — | — | WO | disclosed |
| WO-2024071361-A1 | METHOD FOR ASSESSING COAGULATION INHIBITION ACTIVITY OR COAGULATION PROMOTION ACTIVITY AGAINST COAGULATIVE PROTEIN | 株式会社カネカ | 2024-04-04 | — | — | WO | disclosed |
| WO-2023199010-A1 | TREATMENT OF MUSCLE FIBROSIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2023-10-19 | — | — | WO | disclosed |
| US-20220267736-A1 | PLURIPOTENT STEM CELL AGGREGATION SUPPRESSOR | KANEKA CORPORATION (JP) | 2022-08-25 | — | — | US | disclosed |
| US-11046933-B2 | Induction of pluripotent cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3733836-A1 | CELL AGGREGATION INHIBITOR | Kaneka Corporation (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733837-A1 | CELL AGGREGATION PROMOTING AGENT | Kaneka Corporation (JP) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020203532-A1 | METHOD FOR PRODUCING PLURIPOTENT STEM CELLS | 株式会社カネカ | 2020-10-08 | — | — | WO | disclosed |
| WO-2020203538-A1 | CELL POPULATION INCLUDING PLURIPOTENT STEM CELLS AND PRODUCTION METHOD THEREOF | 株式会社カネカ | 2020-10-08 | — | — | WO | disclosed |
| EP-3708662-A1 | METHOD FOR PRODUCING CULTURED CELL, AND METHOD FOR PRODUCING THERAPEUTIC AGENT FOR SPINAL CORD INJURY DISEASE | Regenesis Science Co., Ltd. (JP) | 2020-09-16 | — | — | EP | disclosed |
| US-20180163181-A1 | INDUCTION OF PLURIPOTENT CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2018-06-14 | — | — | US | disclosed |
| US-9890357-B2 | Method for inducing differentiation of human pluripotent stem cells into intermediate mesoderm cells | KYOTO UNIVERSITY (JP) | 2018-02-13 | — | — | US | disclosed |
| WO-2016081554-A1 | IMMUNOGENIC COMPOSITIONS PREPARED FROM TUMOR CELLS DERIVED FROM PERIPHERAL BLOOD AND ORIGINATING FROM A SOLID TUMOR AND THEIR USE | NEOSTEM ONCOLOGY, LLC (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20140363888-A1 | METHOD FOR INDUCING DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS INTO INTERMEDIATE MESODERM CELLS | KYOTO UNIVERSITY (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | RHOA, MYLK2, MYLK | ROCK2 5/4885ROCK1 4/4885GAA 464/4885 |
| US-20110112053-A1 | PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS | RHOA, LIPG, KDR | ROCK2 9/4885ROCK1 8/4885GAA 323/4885 |
| US-20260028584-A1 | METHOD FOR EVALUATING AGGREGATION-SUPPRESSING ACTIVITY OR AGGREGATION-PROMOTING ACTIVITY ON AGGREGATING PROTEIN USING ORGANOID, AND METHOD FOR PRODUCING ORGANOID | TTR, IAPP, TPM4 | ROCK2 3149/4885ROCK1 3637/4885GAA 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.